EGFR and neoplasm: This is consistent with the molecular epidemiology data that suggest that non-small cell lung cancer individuals with EGFR mutations often present with an “immune-desert” phenotype, where no inflammation is observed within the tumor microenvironment along with low overall TMB, immunological tolerance, and weak immunogenicity (18).